Several genomics and synthetic biology stocks are being highlighted as promising investments, with some outlets suggesting they are noteworthy in 2025 and others in 2026. Stocks mentioned include those of companies such as CRISPR Therapeutics and Beam Therapeutics. The specific stocks and the year in which they are considered promising appear to vary across reports.